BIO:ON Insight #21 · Oct 20, 2026

Europe opens the door, China half-closes its own

Lilly's Foundayo weight-loss pill clears Europe's key hurdle, Beijing floats a ban on foreign takeovers of its biotech platforms, and AbbVie and BMS join the 340B court fight. When the rules change, so does the way you win.

Obesity & metabolicRegulatory & approvalsBD, licensing & M&AMarket access & pricing한국어판 보기

What I learned this week

After reading all three, the idea that the first mover wins looked a little different. Latecomers find a route on price, blocked buyers on structure, and those facing rebates on arithmetic. Next time you read that the rules have changed, ask which routes remain and whose skills just became more valuable. See you next issue. 🙏

Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.

Stories in this issue

FDA Approvals
Lilly's Foundayo weight-loss pill wins a CHMP positive opinion in Europe
Eli LillyFoundayoNovo NordiskWegovy
Pipeline Analysis
China's MOFCOM proposes banning foreign takeovers of key biotech platforms
China's MOFCOMAstraZeneca
Market Trends
AbbVie, BMS, Boehringer and PhRMA move to join the 340B rebate pilot lawsuit
AbbVieBristol Myers SquibbBoehringer IngelheimUS HHS / HRSA

AI summary

1The EMA's CHMP recommended approving Lilly's once-daily GLP-1 pill Foundayo (orforglipron), with 5–11% weight loss over 72 weeks; EC sign-off is pending.
2China's MOFCOM proposed export-control changes that would ban foreign takeovers of cell and gene therapy and siRNA platforms, while still allowing licensing (comments until 15 Nov).
3AbbVie, BMS, Boehringer Ingelheim and PhRMA moved to join the hospitals' lawsuit over the 340B rebate pilot covering 21 drugs.

Relevant rolesMarket accessBDRegulatory affairsSales & marketing

Summary and tags generated by AI from the issue text.

References

1.
The weight-loss pill is coming to Europe: Lilly's Foundayo wins key regulatory backing (opens in a new tab)
Fierce Pharma, Oct 16, 2026
2.
Beijing draws a line: China moves to block foreign takeovers of its crown-jewel biotech platforms (opens in a new tab)
Fierce Biotech, Oct 16, 2026
3.
AbbVie, BMS, Boehringer and PhRMA join hospitals' court fight over 340B rebates (opens in a new tab)
Fierce Healthcare, Oct 15, 2026

Other issues covering the same companies, drugs or topics

Issue #16Sep 15, 2026

Same word, "success" — not the same grade of evidence

Summit and Akeso's ivonescimab beats Keytruda on final overall survival at WCLC in Seoul, AstraZeneca's oral SERD wins FDA approval despite a negative advisory vote, and oral Wegovy resolves obesity in 40% of teens. Same word, "success": three very different grades of evidence.

Oncology & IORegulatory & approvalsObesity & metabolic

Shared: AstraZeneca, Novo Nordisk, Wegovy

Issue #18Sep 29, 2026

One company, three battlegrounds — same week, same headline name

Lilly commits up to $3.35B to China's InnoCare for five undisclosed targets, UK regulators rule Lilly's "transform obesity care" release promoted an unlicensed drug, and Foundayo takes one in three new oral GLP-1 starts after cash-price cuts. One company, three fronts, one week.

BD, licensing & M&ARegulatory & approvalsMarket access & pricingObesity & metabolic

Shared: Eli Lilly, Foundayo

Issue #9Jul 19, 2026

The trial "worked" — so why did nothing change?

Biogen takes its tau drug into Phase 3 despite missing the primary endpoint, the FDA resumes publishing drug rejection letters, and IQVIA data confirms Foundayo's slow start. Why do clinical success and market success keep diverging?

Regulatory & approvalsMarket access & pricingObesity & metabolic